Pediatric Brain Cancer Research Stalls After Federal Funding Cuts to Major Trials
The termination of a key National Cancer Institute consortium has paused critical clinical trials for diffuse intrinsic pontine glioma (D.I.P.G.), a devastating and nearly always fatal childhood brain tumor.
🏥Public HealthPhoto: The New York Times Health
Key points
- Federal funding cuts halted the Pediatric Brain Tumor Consortium, pausing eight clinical trials.
- D.I.P.G. is an incurable pediatric brainstem tumor with an average survival time of under a year.
- The defunding affected trials testing immunotherapies, vaccines, and electrical skull caps.
Diffuse intrinsic pontine glioma, or D.I.P.G., is an inoperable brainstem tumor that primarily affects children between the ages of 4 and 10, with roughly 300 diagnoses annually in the United States. The disease typically leaves patients with a life expectancy of nine to 12 months following diagnosis, as there is currently no standard of care or proven cure once radiation therapy concludes. Families facing this grim prognosis often turn to clinical trials as their only remaining option to extend or save their child's life.
However, recent shifts in federal research funding have disrupted these avenues of hope. In August 2025, the National Cancer Institute opted not to renew the $4 million annual grant for the Pediatric Brain Tumor Consortium, which had served as a cornerstone of government-backed pediatric brain cancer research. The decision led to the closure or pausing of eight ongoing trials across 16 elite participating hospitals. Among the affected research were early-stage studies investigating novel immunotherapies, specialized vaccines, laser treatments, and a cranial device delivering electrical stimulation to the brain.
While officials described the move as a consolidation aimed at improving efficiencies, the sudden halt has forced families to scramble for alternative treatments, such as the Phase 2 TarGeT-A trial at Nationwide Children's Hospital in Columbus, Ohio. Experts note that observational impacts on drug development and trial accessibility can severely delay future therapeutic breakthroughs for rare and aggressive pediatric cancers. What to know: D.I.P.G. trials remain limited, and families should consult pediatric oncologists and specialized advocacy networks to navigate experimental treatment options.
Source The New York Times Health — nytimes.com/2026/11/15/well/research-stalls-for-a-year-into-a-cance… ↗
Read next
❤️Conditions & CareBlood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma
Researchers have identified a specific RNA signature in blood plasma that may help predict how well lymphoma patients respond to CAR T-cell therapy.
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
❤️Conditions & CareMigraine and Smoking Linked to Increased Early Stroke Risk in Women
A large-scale study suggests that people who have given birth and experience migraines while also smoking face a significantly higher risk of stroke before age 60.
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…